System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Diego Bagnasco is an expert in Immunology at Ospedale Policlinico San Martino (Italy). As of October 2026, ScienceLeadR ranks Diego Bagnasco in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Diego Bagnasco has authored 167 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 507 (community average: 125). How the SLR is computed.

LeadR Profile

Diego Bagnasco Ospedale Policlinico San Martino Italy
507 ScienceLeadR Reputation 507

Unlock

Register Login
Network Map

Immunology

Subspecialties: Pulmonology - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2014 - 2026
Source: PubMed

University of Genoa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 167

Citations

Citations: 3 044 1st author: 44 Last author: 9 Unique author: 0

Main journals

World Allergy Organ J 18
Allergy 8
Curr Opin Allergy Clin Immunol 8
Respir Med 8
05.01 - Airway pharmacology and treatment 7

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Adherence To Inhaled Treatment Is Associated With Better Disease Control And Quality Of Life In Mild-To-Moderate Asthma.
PMID 42660367 — quality of life, therapeutics, asthma, smoking		Respir Med20260
Staphylococcus Aureus Toxins and Asthma: Pathophysiological Mechanisms, Clinical Relevance, and Therapeutic Implications in the Biologics Era.
PMID 42646747 — cells, superantigens, extracellular vesicles, staphylococcus, enterotoxins, eosinophils, allergens, biofilms, immunity, staphylococcus aureus, therapeutics, asthma, t-lymphocytes, microbiota, dermatitis, atopic		Toxins (Basel)20261
A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.
PMID 42571238 — blood, adrenal cortex hormones, eosinophils, therapeutics, asthma		World Allergy Organ J20260
Long-term effects of sublingual immunotherapy (SLIT) in preventing the development of asthma in allergic rhinitis: Revision of 15-year follow-up.
PMID 42565174 — sublingual immunotherapy, rhinitis, allergic, immunotherapy, rhinitis, therapeutics, asthma		World Allergy Organ J20260
The PEACE-24 Study: Tezepelumab Improves Functional Exercise Capacity and Asthma Control in Severe Asthma.
PMID 42448002 — exercise, exercise tolerance, asthma, physical exertion		Respir Med20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 2 1

By status:

Recruiting 2

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of KT 621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
2025-523180-38-00 — safety, therapeutics, asthma		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS